Anaemia during targeted anticancer therapy: pathogenesis, clinical features and modern correction approaches
Open Access
- 26 June 2026
- journal article
- Published by Publishing House ABV Press in Supportive Therapy in Oncology
- Vol. 3 (1) , 51-60
Abstract
Aim. To systematise current data on the mechanisms of anaemia development with major targeted anticancer drug classes, evaluate its impact on quality of life and summarise modern correction approaches. Materials and methods. A narrative literature review was performed searching PubMed, eLIBRARY and Cochrane Library with no date restrictions. Randomised clinical trials, meta-analyses, pharmacovigilance studies and current clinical guidelines (ESMO, ASCO/ASH) were analysed for the following drug classes: antibody–drug conjugates (ADCs), PARP inhibitors (PARPi), tyrosine kinase inhibitors and immune checkpoint inhibitors. Results. Anaemia occurs in 30–80 % of cancer patients and represents an independent prognostic factor for worse overall survival. ADC haematological toxicity is off-target and payload-driven: conjugates based on monomethylauristatin E carry the highest rates of severe anaemia. PARPi cause anaemia as a class effect via disruption of PARP-2-dependent erythroid differentiation. Tyrosine kinase inhibitors exert haematotoxicity through molecularly specific pathways, including disruption of erythrocyte membrane integrity. Immune checkpoint inhibitors are associated with immune-mediated haemolytic anaemia and aplastic syndrome. Among correction approaches, intravenous iron preparations and sucrosomial iron overcome the hepcidin-mediated functional block unachievable with classical oral salts. Erythropoiesis-stimulating agents are indicated under strict conditions given thromboembolic risk and potential immunosuppressive effects on the tumour microenvironment. Conclusion. Pathogenetically sound correction of anaemia during targeted therapy requires a differentiated approach accounting for the development mechanism, type of iron deficiency and targeted agent class. Blood count monitoring no later than 2 weeks from the first cycle start is mandatory for patients receiving ADCs, PARPi and immune checkpoint inhibitors.Keywords
This publication has 26 references indexed in Scilit:
- Anaesthetic considerations for patient blood management in cancer surgery: a narrative reviewAnaesthesia Critical Care & Pain Medicine, 2025
- Anaemia in cancer patients: Advances and challenges in the era of precision oncologyCritical Reviews in Oncology/Hematology, 2025
- LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancerAnnals of Oncology, 2023
- EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinomaAnnals of Oncology, 2023
- Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysisCancer, 2022
- Randomized trial of sucrosomial iron supplementation in patients with chemotherapy-related anemia treated with ESASupportive Care in Cancer, 2022
- Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studiesSupportive Care in Cancer, 2015
- Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated AnemiaJAMA, 2008
- The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patientsEuropean Journal of Cancer, 2004
- Prevalence and outcomes of anemia in cancer: a systematic review of the literatureThe American Journal of Medicine, 2004